Funds will support the development of Shinobi's lead iPS-T cell program targeting GPC3+ tumors. Shinobi also expands its investor syndicate, with the addition of Yosemite and Mitsubishi UFJ Capital, bringing the company's total funding to $119M . SAN FRANCISCO and KYOTO, Japan , Aug.
6, 2024 /PRNewswire/ -- Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS cell therapies, today announced that it has been awarded up to $59M in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). The grant will be used to support the development of Shinobi's lead program, an iPS-T cell therapy targeting GPC3+ solid tumor cancers. "AMED is one of the leading institutions worldwide for supporting breakthroughs in medicine and biotechnology, and this grant is a significant vote of confidence in Shinobi's technology," said Yasumichi Hitoshi, M.
D., Ph.D.
, Chief of Staff and Shinobi Japan's Representative Director. "We are thrilled to have the support of AMED as we work toward realizing the therapeutic potential of iPSCs." Shinobi also announced an extension of its Series A round , bringing the company's total funding to $119M , with the addition of Yosemite and Mitsubishi UFJ Capital as investors.
Cell therapies have successfully been used to treat blood cancers and other intractable diseases, but manufacturing costs continue to render these therapies inaccessible to many patients around the world. Shinobi's immune evasive iPS-T cell technology, built upon a decade of research by scientific co-founders Tobias Deuse, M.D.
and Shin Kaneko , M.D., Ph.
D., enables a new class of off-the-shelf cell therapies that work with, not against, the patient's immune system. Shinobi was recently recognized by Japanese Prime Minister Fumio Kishida as being at the forefront of innovative cancer drug development.
This recognition highlights Shinobi's role in bridging Japanese biotech startups with U.S. and global venture capital ecosystems.
"iPS cell therapies have the potential to transform patient care across a wide range of diseases while improving access in populations with high unmet needs, and much of the most exciting work in the field is happening in Japan ," said Dan Kemp , Ph.D., CEO at Shinobi.
"This AMED grant is a major statement of conviction by the Japanese agency and will help accelerate our lead oncology program toward the clinic." The company has also recently cemented partnerships with Panasonic around scaled manufacturing and Anocca for TCR discovery and development. About Shinobi Therapeutics Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies.
Based on the research of scientific co-founders Shin Kaneko , M.D., Ph.
D., at Kyoto University and Tobias Deuse, M.D.
, at University of California, San Francisco , Shinobi has created a new allogeneic CD8 iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. For more information, please visit www.shinobitx.
com . About AMED Founded in 2015, AMED is a government funding agency in Japan tasked with accelerating medical innovation and pushing for global competitiveness in healthcare. The agency supports projects that range from basic research, all the way to clinical trials–promoting the translation of scientific discoveries into practical healthcare solutions.
Media Contact: [email protected] SOURCE Shinobi Therapeutics.
